Descriptive Observational Study ALK-2016-CPHG
NCT03718117
·
clinicaltrials.gov ↗
COMPLETED
Status
73
Enrollment
INDUSTRY
Sponsor class
Conditions
NSCLC
Crizotinib
ALK Gene Rearrangement or ROS1 Gene Rearrangement
Sponsor
Pfizer
Collaborators
[object Object]